TEC: Evidence Based Therapeutics
Therapeutics Education Collaboration
Medication Mythbusters – Home of the Best Science (BS) Medicine Podcast

Episode 290: PREMIUM – Empagliflozin and the EMPA-REG OUTCOME study

In episode 290, James and Mike address listener demands for a discussion on the latest diabetes outcomes trial that looked at empagliflozin, a new class of medications for type-2 diabetes. This study actually showed the group who received this new drug had a reduction in CVD events and other clinically important outcomes. While this is a good finding, upcoming trials of other medications in this class will help put this drug into a context.

Show notes

1) EMPA-REG OUTCOME

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type-2 Diabetes

NEJM 2015 DOI: 10.1056/NEJMoa1504720 

Listening to this episode is for premium podcast members only. If you already have a membership, login to your account. If you aren't yet a premium subscriber, sign up today!

Search

BS Medicine Podcast

The 2026 MEME Conference – May 8-9, 2026

REGISTRATION IN JANUARY 2026

Making Evidence Matter For Everyone | May 8-9, 2026
From the clinicians who brought you the Best Science Medicine Course and the Meds Conference, as well as the BS Medicine Podcast and Tools for Practice

hectalks.com

PEER Tools

BIG ANNOUNCEMENT

THE NUTRITION PROPOSITION BOOK

Check it out at nutritionproposition.com and think about picking up a copy on Amazon. All the evidence you ever wanted about nutrition and the only nutrition book that won’t tell you what to eat.

 

Search

Recent Posts

Archives

Categories

Meta